The high incidence, long treatment duration, and multiple lines of therapy in the treatment of breast cancer represent strong commercial opportunity for drug development. The CDK4/6 inhibitors (…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
Obesity is a significant public health concern in the G7 countries and is growing as an epidemic. The body of evidence highlighting the physical and economic impact of obesity on society is…
We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio,…
The acute lymphoblastic leukemia (ALL) therapy market is growing steadily, fueled by innovations in the treatment paradigm. The availability of premium-priced branded agents prescribed in multidrug…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
China has the highest incidence of gastroesophageal cancer in the world. Chemotherapy is the main treatment, although targeted therapies such as trastuzumab (an anti-HER2 MAb for HER2-positive…
Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…
Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…
Clarivate expects the next 10 years to be transitional for patients with hemophilia A (with and without inhibitors) owing to the entry of several novel therapeutic options into the market. With the…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…